Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
41.22
-1.11 (-2.62%)
At close: Dec 10, 2025, 4:00 PM EST
41.04
-0.18 (-0.44%)
After-hours: Dec 10, 2025, 7:54 PM EST
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Rigel Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $43.2, which forecasts a 4.80% increase in the stock price over the next year. The lowest target is $24 and the highest is $57.
Price Target: $43.2 (+4.80%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Rigel Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $23 → $42 | Hold → Strong Buy | Upgrades | $23 → $42 | +1.89% | Nov 5, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $32 → $38 | Hold | Maintains | $32 → $38 | -7.81% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +38.28% | Oct 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $23 → $32 | Hold | Maintains | $23 → $32 | -22.37% | Aug 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | -44.20% | May 7, 2025 |
Financial Forecast
Revenue This Year
296.76M
from 179.28M
Increased by 65.53%
Revenue Next Year
297.41M
from 296.76M
Increased by 0.22%
EPS This Year
6.69
from 0.99
Increased by 575.36%
EPS Next Year
4.40
from 6.69
Decreased by -34.23%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 310.4M | 374.0M | ||||
| Avg | 296.8M | 297.4M | ||||
| Low | 279.4M | 258.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 73.1% | 26.0% | ||||
| Avg | 65.5% | 0.2% | ||||
| Low | 55.9% | -12.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.95 | 5.45 | ||||
| Avg | 6.69 | 4.40 | ||||
| Low | 6.36 | 3.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 602.1% | -18.5% | ||||
| Avg | 575.4% | -34.2% | ||||
| Low | 542.4% | -47.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.